Ira Hebold Haraldsen
Oslo University Hospital
Development of a Novel F18-PET tracer for early diagnosis of Alzheimers Dementia
Alzheimer's disease & other dementias
Our primary objective is to develop a F18-GnRH PET-tracer for pre-symptomatic diagnosis of AD.
Our secondary objectives are:
Development of a 3rd generation library of compounds to optimize the brain uptake, specific binding and metabolic stability.
Screen for lead candidates according to selection criteria
Estimate the binding potential of GnRH tracers in rodent brain sections (Bmax/Kd) to assess the expected signal strength of specific binding of the tracer.
Estimate the binding potential of GnRH tracer s in human brain sections (Bmax/Kd) (as above).
Dynamic in vivo PET in rats (correlation to receptor distribution as measured by immunohistochemical staining patterns).
Dynamic displacement / pre-blockage of tracer uptake by treatment with a non-radioac tive GnRH-affine compound (for quantification/specificity of signal).
Outsourcing of ADMET-studies (Absorption, distribution, metabolism, excretion, toxicity) for preparation of clinical applications